Cytopenias after BCMA CAR-T in MM
| . | CHIP . | P value . | |
|---|---|---|---|
| Yes (n = 57) . | No (n = 47) . | ||
| Anemia | |||
| Grade 3, n (%) | 29 (51) | 26 (55) | .77 |
| Grade 4, n (%) | 3 (5) | 2 (4) | |
| ≥1 pRBC transfusion, n (%) | 30 (53) | 21 (45) | .44 |
| Median no. of transfusions (range)∗ | 4 (1-34) | 3 (1-12) | .71 |
| Risk of transfusion dependence, % | |||
| Day +28 | 31 | 15 | .01 |
| Day +100 | 15 | 0 | |
| Day +365 | 14 | 0 | |
| Thrombocytopenia | |||
| Grade 3, n (%) | 7 (12) | 11 (23) | .67 |
| Grade 4, n (%) | 22 (39) | 17 (36) | |
| ≥1 platelet transfusion, n (%) | 20 (35) | 14 (30) | .68 |
| Median no. of transfusions (range)∗ | 5 (1-47) | 4 (1-25) | .65 |
| TPO receptor agonist, n (%) | 8 (14) | 1 (2) | .04 |
| Risk of transfusion dependence, % | |||
| Day +28 | 24 | 15 | .06 |
| Day +100 | 13 | 0 | |
| Day +365 | 13 | 0 | |
| Neutropenia | |||
| Grade 3, n (%) | 7 (12) | 10 (21) | .68 |
| Grade 4, n (%) | 44 (77) | 35 (74) | |
| ≥1 G-CSF injection, n (%) | 50 (88) | 43 (91) | .75 |
| Median no. of G-CSF (range)∗ | 6 (1-37) | 3 (1-28) | <.001 |
| Risk of transfusion dependence, % | |||
| Day +28 | 63 | 43 | <.001 |
| Day +100 | 30 | 9 | |
| Day +365 | 15 | 0 | |
| . | CHIP . | P value . | |
|---|---|---|---|
| Yes (n = 57) . | No (n = 47) . | ||
| Anemia | |||
| Grade 3, n (%) | 29 (51) | 26 (55) | .77 |
| Grade 4, n (%) | 3 (5) | 2 (4) | |
| ≥1 pRBC transfusion, n (%) | 30 (53) | 21 (45) | .44 |
| Median no. of transfusions (range)∗ | 4 (1-34) | 3 (1-12) | .71 |
| Risk of transfusion dependence, % | |||
| Day +28 | 31 | 15 | .01 |
| Day +100 | 15 | 0 | |
| Day +365 | 14 | 0 | |
| Thrombocytopenia | |||
| Grade 3, n (%) | 7 (12) | 11 (23) | .67 |
| Grade 4, n (%) | 22 (39) | 17 (36) | |
| ≥1 platelet transfusion, n (%) | 20 (35) | 14 (30) | .68 |
| Median no. of transfusions (range)∗ | 5 (1-47) | 4 (1-25) | .65 |
| TPO receptor agonist, n (%) | 8 (14) | 1 (2) | .04 |
| Risk of transfusion dependence, % | |||
| Day +28 | 24 | 15 | .06 |
| Day +100 | 13 | 0 | |
| Day +365 | 13 | 0 | |
| Neutropenia | |||
| Grade 3, n (%) | 7 (12) | 10 (21) | .68 |
| Grade 4, n (%) | 44 (77) | 35 (74) | |
| ≥1 G-CSF injection, n (%) | 50 (88) | 43 (91) | .75 |
| Median no. of G-CSF (range)∗ | 6 (1-37) | 3 (1-28) | <.001 |
| Risk of transfusion dependence, % | |||
| Day +28 | 63 | 43 | <.001 |
| Day +100 | 30 | 9 | |
| Day +365 | 15 | 0 | |
TPO, thrombopoietin receptor agonist.
Among patients who received a transfusion/injection.